Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599505 | 1.00 | SMYD2 (0.49) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL599980 | 0.78 | SMYD2 (0.48) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15348146 | 0.78 | CYP3A4 (0.54) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5566651 | 0.74 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5569919 | 0.74 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL12192737 | 0.72 | SMYD2 (0.48) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL19979001 | 0.72 | SMYD2 (0.48) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17686386 | 0.71 | SMYD2 (0.46) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL706843 | 0.71 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25062462 | 0.71 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | SMYD2 2969/4885CYP3A4 728/4885HTT 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.